Furthermore, the combination of SHPi (SHP099) with PI3K targeting therapy prevented MAPK activation, confirming that the PI3K and MAPK pathways often play an important role in the oncogenic activity of PTPN11 mutated NSCLC. The gene discussed is PTPN11; the disease is non-small cell lung carcinoma.